



## Overview

This is a user-friendly interface using R (R CORE TEAM, 2020) package Shiny (CHANG et al., 2020) to run the three-compartment mathematical model developed in Rodrigues (2019). This model describes the tumor response to CAR T cell immunotherapy in immunodeficient mouse models. It encompasses interactions between tumor cells, effector and long-term memory CAR T cells such as tumor induced immunosuppression effects, conversion of memory T cells into effector T cells in the presence of tumor cells, and individual specificity considered as uncertainties in the model parameter values (RODRIGUES et al., 2020). Other simulation results are already published in Barros et al. (2020).

## Basic usage

**Running CARTmath:** users can choose a pre-set dataset or customize every option. Datasets generate the same figures from Rodrigues et al. (2020). On “Mathematical Model” one can view the model to be simulated. To generate the graphic result, click on “Run Simulation” button on “Simulation”. Wait for a few seconds and the corresponding simulation result will be displayed.

**Running CARTmath Customized mode:** to customize your run, choose one of the “Customized” options on Dataset box, and make any changes on parameters as tumor or CAR T cell numbers.

**Modifying previous simulations:** after choosing a pre-set dataset, users can modify any basic or advanced parameters. To generate a new graphic, click on “Run Simulation” button on “Simulation”. Wait for a few seconds and the new graphic will be displayed.

**Graphics download directly from SETUP page:** pass the mouse over the graphic and click on the “camera” symbol. Download graphic on png format.

**Graphics customizations:** at the “Graphics” page, users can customize graphic “y” and “x” axis labels, scales, and formats for each population in an independent plot. Line width, color, and grid can also be changed. The graphic with the three populations will acquire all changes made by each population graphic independently and it is possible to choose by a single or double y-axis.

**Table download:** at the “Table” page, users can visualize and download the table with the simulation values for each cell population. For simplification, one value for each day is displayed for each population. Rows order can be changed clicking on the arrows near each population title in increasing or decreasing values. The simulation results are available for download in the form of tables in csv format containing all the simulation steps (“Download full table” button) or in a reduced version (“Download summarized table” button).

**Report:** a report is generated for each simulation containing the values of all basic and advanced model settings and graphic with the three cell populations. This report can be downloaded in pdf format by clicking on “Download report” button.

**CAUTION:** in the Customized mode, the advanced parameters assigned a priori must be carefully evaluated. Different types of tumor cells and CAR T may require significant variations in their values. A calibration set will be available in the next version of CARTmath.

## Available Datasets

### I. CAR T Immunotherapy in HDLM-2 tumor (RODRIGUES et al., 2020 – Figure 3a)

Hodgkin's Lymphoma tumor cell lineage HDLM-2 in NSG mice and CAR T 123 immunotherapy (against CD123 antigen). Experimental data from Ruella et al. (2017) - Figure 4.

**Initial conditions:**

Tumor cell number ( $T$ ):  $2.10^6$  cells.

CAR T cell number ( $C_T$ ):  $1.10^6$  cells.

CAR T cell injection at day 42.

### II. CAR T Immunotherapy with Challenge in HDLM-2 tumor (RODRIGUES et al., 2020 – Figure 2a)

Hodgkin's Lymphoma tumor cell lineage HDLM-2 in NSG mice and CAR T 123 immunotherapy. Challenge at day 250. Experimental data from Ruella et al. (2017) - Figure 5.

**Initial conditions:**

Tumor cell number ( $T$ ):  $2.10^6$  cells.

CAR T cell number ( $C_T$ ):  $2.10^6$  cells.

CAR T cell injection at day 42.

Challenge with  $1.10^6$  tumor cells at day 250.

### III. CAR T Immunotherapy with Fractionated Doses in HDLM-2 tumor (RODRIGUES et al., 2020 – Figure 3d)

Hodgkin's Lymphoma tumor cell lineage HDLM-2 in NSG mice and CAR T 123 immunotherapy applied according to a hypothetical scenario of dose fractionation.

**Initial conditions:**

Tumor cells ( $T$ ):  $2.10^6$  cells.

CAR T cell ( $C_T$ ):  $5.10^5$  cells/dose.

CAR T cell injection at days 42, 49, 56, 63.

### IV. CAR T Immunotherapy in RAJI tumor (RODRIGUES et al., 2020 - Figure 2b)

RAJI tumor cell in SCID/Beige mice. CAR T 19 immunotherapy (against CD19 antigen). Experimental data from Ninomiya et al. (2015) - Figure 2.

**Initial conditions:**

Tumor cells ( $T$ ):  $3.10^6$  cells.

CAR T cell ( $C_T$ ):  $1.10^7$  cells.

CAR T cell injection at day 7.

### V. CAR T Immunotherapy in RAJI-IDO tumor (RODRIGUES et al., 2020 - Figure 5a)

RAJI-IDO tumor cell in SCID/Beige mice. CAR T 19 immunotherapy. Experimental data from Ninomiya et al. (2015) - Figure 3.

**Initial conditions:**

Tumor cells ( $T$ ):  $3.10^6$  cells.

CAR T cell ( $C_T$ ):  $1.10^7$  cells.

CAR T cell injection at day 7.

## VI. CAR T Immunotherapy with IDO inhibitor (1-MT) in RAJI-IDO tumor (RORIGUES et al., 2020 - Figure 5b)

RAJI-IDO tumor cell in SCID/Beige mice. CAR T 19 immunotherapy with IDO inhibitor (1-MT). Experimental data from Ninomiya et al. (2015) - Figure 3.

### Initial conditions:

Tumor cells ( $T$ ):  $3 \cdot 10^6$  cells.

CAR T cell ( $C_T$ ):  $1 \cdot 10^7$  cells.

CAR T cell injection at day 7.

## VII. “Custom slow growth (HDLM-2)” or “Custom rapid growth (RAJI)”

By choosing one of these options, the user can modify any basic or advanced settings for the slow tumor growth (referred to the Hodgkin’s Lymphoma tumor cell lineage HDLM-2) or rapid tumor growth (referred to the RAJI tumor cell lineage).

## Basic Parameters

**Dataset:** choose a pre-set dataset or a full customized option.

**Maximum simulation time (days):** set the maximum simulation time wanted to evaluate CAR T cell immunotherapy results.

**Tumor cell number ( $\times 10^6$ ):** set the initial tumor cell dose injected into the mice.

**Dose type:** set if it will be administrated a single dose of CAR T cell or several doses (Fractionated). If Fractionated dose is selected, set the number of doses to be performed.

**CAR T cell number ( $\times 10^6$ ):** set the CAR T cell dose injected into the mice. If Fractionated dose is selected, set each corresponding dose.

**Day of CAR T cell injection:** set the day after tumor injection when CAR T cell are inoculated. If Fractionated dose is selected, set the injection day of each dose.

**Challenge:** assign challenge if a second tumor cell injection will be performed.

**Challenge day:** set how many days after the first tumor injection a second injection will be performed.

**Number of tumor cell in challenge ( $\times 10^6$ ):** set how many tumor cells will be injected at the challenge.

## Advanced Parameters

Advanced parameters estimation was performed with *in vitro* and *in vivo* experimental results from Ruella et al. (2017) to the Hodgkin’s Lymphoma tumor cell lineage HDLM-2 and Ninomiya et al. (2015) to the RAJI tumor.

- **Tumor proliferation rate ( $r$ ):**  $\ln(2)/td$ , in which “td” is the time (in days) it takes for the number of tumor cells to double. Unit: 1/day.
- **Tumor death rate by CAR T ( $\gamma$ ):** probability of tumor cell death per day due to contact with effector CAR T cells. Unit: 1/cell.day.
- **Inverse of tumoral support capacity ( $b$ ):** the inverse of the maximum number of tumor cells that the environment can sustain. Unit: 1/cell.

- **CAR T proliferation rate ( $\phi$ )**:  $\ln(2)/tc$ , in which “tc” is the time (in days) it takes for the number of CAR T cells to double. Unit: 1/day.
- **CAR T death rate ( $\mu_T$ )**: inverse of the half-life time of effector CAR T cells. Unit: 1/day.
- **CAR T inhibition ( $\alpha$ )**: probability of effector CAR T cell inhibition per day caused by the tumor. For example, the action of PD-L1/PD-1 signaling. Unit: 1/cell.day.
- **Memory conversion rate ( $\rho$ )**: differentiation rate of effector CAR T cells into memory CAR T cells. Unit: 1/day.
- **Memory death rate ( $\mu_M$ )**: inverse of the half-life time of memory CAR T cells. Unit: 1/day.
- **Conversion coefficient ( $\theta$ )**: proportion of memory CAR T cells which are converted into effector CAR T cells per day driven by antigen contact on tumor cells. Unit: 1/cell.day.
- **Numerical response of the conversion ( $\epsilon$ )**: proportion of differentiated effector CAR T cells which become memory CAR T cells. Unit: dimensionless.
- **Numerical parameter,  $\Delta t$  value**: Simulation time step size. Typical values range from  $10^{-2}$  up to  $10^{-6}$  (day). In general, smaller time steps produce more accurate results but require more computational processing. A  $\Delta t = 10^{-2}$  yields convergent solutions for Ruella et al (2017) experiments.

The button “Reset advanced parameter values” enable the user to reset the original values of the advanced parameters.

## References

- BARROS, L. R. C.; RODRIGUES, B. J.; ALMEIDA, R. C. (2020). CAR-T cell goes on a mathematical model. *Journal of Cellular Immunology*, 2(1):31-37. ISSN: 2689-2812. <https://www.scientificarchives.com/article/cart-cell-goes-on-a-mathematical-model>
- CHANG, W.; CHENG, J.; ALLAIRE, J. J.; XIE, Y.; MCPHERSON, J. (2020). *Shiny*: web application framework for R. <http://CRAN.R-project.org/package=shiny>
- NINOMIYA, S. et al. (2015). Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. *Blood, The American Society of Hematology*, 125(25):3905-3916. doi: 10.1182/blood-2015-01-621474.
- RODRIGUES, B. J. *Modelagem matemática da imunoterapia com células CAR T* (2019). 106 p. Dissertação (Mestrado em Modelagem Computacional) - Laboratório Nacional de Computação Científica, Petrópolis, 2019. <https://drive.google.com/file/d/1Mrp28fw-FZqoBIMGTuYf2srTFC-qfE9a/view>
- RODRIGUES, B. J.; BARROS, L. R. C.; ALMEIDA, R. C. (2020). Three-compartment model of CAR T-cell immunotherapy. *bioRxiv*. doi: <https://doi.org/10.1101/779793>. <https://www.biorxiv.org/content/10.1101/779793v2>
- RUELLA, M. et al. (2017). Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. *Cancer Discovery*, 7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850.
- R CORE TEAM (2020). *R*: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <http://www.R-project.org/>

## Development team

Andréa M. P. Valli, Brendon de J. Rodrigues, Emanuelle A. Paixão, Gustavo T. Naozuka,  
Luciana R. C. Barros and Regina C. Almeida.

